title: The challenges of developing new tuberculosis vaccines.
abstract: The World Health Organization estimates that tuberculosis is causing nearly two million deaths annually, mostly in developing countries. Widespread administration of the current tuberculosis vaccine to newborns is not a reliable route for preventing the disease in adults, the population that drives the epidemic. Several new vaccine candidates are in development, and a few have entered clinical trials. However, the field faces formidable scientific and policy challenges. A collaborative approach to solving scientific, policy, and resource obstacles--as well as new partnerships among emerging economies and vaccine development organizations--will be critical to developing a new tuberculosis vaccine that could achieve its public health potential to save lives and reduce the burden of disease.
authors.affiliation: Aeras, Rockville, Maryland, USA.lbarker@aeras.org
authors.forename: Lewellys F
authors.initials: LF
authors.lastname: Barker
authors.forename: Annmarie E
authors.initials: AE
authors.lastname: Leadman
authors.forename: Bartholt
authors.initials: B
authors.lastname: Clagett
mesh_terms: D003299:Cooperative Behavior; D017277:Drug Approval / Q000458:organization & administration*; D006801:Humans; D009161:Mycobacterium / Q000187:drug effects / Q000276:immunology*; D014376:Tuberculosis / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000600:supply & distribution*
chemical_list: D032581:Tuberculosis Vaccines